Drug Trial Radar · NCT01987297
Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL
Last checked: Nov 20, 2026Latest source record: Aug 19, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
738
Planned (sponsor's estimate)
Start
Jun 2012
Primary completion
Dec 31, 2020
Study completion Dec 31, 2020
Sponsor
- Lead sponsor
- Shanghai Jiao Tong University School of MedicineAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Tang-Du Hospital; Peking University People's Hospital; First Affiliated Hospital of Zhejiang University; Tongji Hospital; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; First Hospital of China Medical University; Southwest Hospital, China; West China Hospital; Ningbo No. 1 Hospital; Qilu Hospital of Shandong University; Shandong Provincial Hospital; Union hospital of Fujian Medical University; First Affiliated Hospital of Guangxi Medical University; Guangdong Provincial People's Hospital; First Affiliated Hospital, Sun Yat-Sen University; The First Affiliated Hospital of Soochow University; The First Affiliated Hospital with Nanjing Medical University; The Second Affiliated Hospital of Dalian Medical University; Nanfang Hospital, Southern Medical University; The First Affiliated Hospital of Anhui Medical University; Institute of Hematology & Blood Diseases Hospital, China
- First posted
- Nov 19, 2013
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In this prospective randomized study for patients with newly diagnosed acute promyelocytic leukemia, patients will be randomized (1:1) into two groups which receive retinoic acid and arsenic trioxide based treatment versus retinoic acid and chemotherapy based regimen.
Conditions
- Acute Promyelocytic Leukemia
Interventions
ATRA+ArsenicDrug
ATRA: 25mg/m2 daily;Induction: D1 to CR; Consolidation: D1-14 each course; Maintenance: D1-14 each course. Arsenic: 0.16mg/kg daily. Induction: D1 to CR; Consolidation: low/intermediate-risk patients 28 days each course; high-risk: 14 days each course; Maintenance: 14 days on and off each course. Idarubicin 8mg/m2 or Daunorubicin 45mg/m2 daily. Induction: 3-4 days in high-risk patients or intermediated-risk patients with leukocytosis developed during induction therapy. Consolidation: 3 days in high-risk patients in first 2 courses. MTX: 15mg/m2 qw Maintenance: qw x 4 in each course for high-risk patients.
ATRA+ChemoDrug
ATRA: 25mg/m2 daily;Induction: D1 to CR; Consolidation: D1-14 each course; Maintenance: D1-14 each course. Arsenic: 0.16mg/kg daily. Induction: D1 to CR; Maintenance: 14 days on and off each course. Idarubicin 8mg/m2 or Daunorubicin 45mg/m2 daily. Induction: 3-4 days in high-risk patients or intermediated-risk patients with leukocytosis developed during induction therapy. Consolidation: 3 days in all patients in 2 courses. Cytarabine: 150mg/m2 or 1g/m2. Consolidation: 150mg/m2 daily x 7 days in high risk patients in first 2 courses; 1g/m2 q12 x 6 doses in third course. MTX: 15mg/m2 qw Maintenance: qw x4 in each course for high-risk patients.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Disease free survival (DFS)Time frame: 3 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Department of Hematology
Shanghai, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.